logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Aromatic Amino Acid class drugs

    FiltersReset Filters
    7 results

    • carbidopa and levodopa

      (Carbidopa and levodopa)
      Advagen Pharma Ltd
      Usage: Carbidopa and levodopa extended-release tablets are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.

    • carbidopa-levodopa

      (carbidopa and levodopa)
      Advagen Pharma Ltd.,
      Usage: Carbidopa and levodopa tablets are indicated for treating Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide or manganese intoxication. Carbidopa enhances levodopa's effectiveness, allowing lower doses, reducing nausea, and facilitating faster titration.

    • dhivy

      (Carbidopa Levodopa)
      Avion Pharmaceuticals, LLC
      Usage: DHIVY is indicated for treating Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.

    • duopa

      (Carbidopa and Levodopa)
      AbbVie Inc.
      Usage: DUOPA® is indicated for treating motor fluctuations in patients with advanced Parkinson’s disease.

    • inbrija

      (levodopa)
      Merz Pharmaceuticals, LLC, a subsidiary of Merz Therapeutics GmbH
      Usage: INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease who are receiving carbidopa/levodopa therapy.

    • rytary

      (Carbidopa and Levodopa)
      Amneal Pharmaceuticals LLC
      Usage: RYTARY is indicated for treating Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism associated with carbon monoxide or manganese intoxication.

    • vyalev

      (foscarbidopa/foslevodopa)
      AbbVie Inc.
      Usage: VYALEV is indicated for treating motor fluctuations in adults with advanced Parkinson's disease.